Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib

First - despite what you'll hear - it is pirTobrutinib, not pirobrutinib. Second - lots of great information on the current state of targeted therapies in adjuvant NSCLC and on two exciting new drugs: elacestrant and pirtobrutinib.